KR100915893B1 - Herb Extracts and Functional Food using the same for Obviating and Curing Hangover - Google Patents
Herb Extracts and Functional Food using the same for Obviating and Curing Hangover Download PDFInfo
- Publication number
- KR100915893B1 KR100915893B1 KR1020060099815A KR20060099815A KR100915893B1 KR 100915893 B1 KR100915893 B1 KR 100915893B1 KR 1020060099815 A KR1020060099815 A KR 1020060099815A KR 20060099815 A KR20060099815 A KR 20060099815A KR 100915893 B1 KR100915893 B1 KR 100915893B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- hangover
- alcohol
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 32
- 239000000284 extract Substances 0.000 title claims abstract description 21
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 239000012676 herbal extract Substances 0.000 claims abstract description 27
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 16
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 16
- 241000018646 Pinus brutia Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 244000305267 Quercus macrolepis Species 0.000 claims abstract description 15
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 14
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 14
- 229940010454 licorice Drugs 0.000 claims abstract description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052737 gold Inorganic materials 0.000 claims abstract description 11
- 239000010931 gold Substances 0.000 claims abstract description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052709 silver Inorganic materials 0.000 claims abstract description 10
- 239000004332 silver Substances 0.000 claims abstract description 10
- 240000000425 Chaenomeles speciosa Species 0.000 claims abstract description 9
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims abstract description 9
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims abstract description 9
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 8
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 8
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 8
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 13
- 240000006891 Artemisia vulgaris Species 0.000 claims description 8
- 235000017788 Cydonia oblonga Nutrition 0.000 claims description 7
- 241000411851 herbal medicine Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 241000272875 Ardeidae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 83
- 240000001851 Artemisia dracunculus Species 0.000 abstract description 6
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 60
- 238000010171 animal model Methods 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 238000013222 sprague-dawley male rat Methods 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000020510 functional beverage Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000013334 alcoholic beverage Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 150000002013 dioxins Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000218691 Cupressaceae Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940124600 folk medicine Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 2
- 229940093767 glabridin Drugs 0.000 description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- -1 kphene Chemical compound 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- NXLOLUFNDSBYTP-UHFFFAOYSA-N retene Chemical compound C1=CC=C2C3=CC=C(C(C)C)C=C3C=CC2=C1C NXLOLUFNDSBYTP-UHFFFAOYSA-N 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- CJUFYKORDZSOLF-INIZCTEOSA-N 6-[(3r)-8,8-dimethyl-3,4-dihydro-2h-pyrano[2,3-f]chromen-3-yl]-2,2-dimethylchromen-5-ol Chemical compound O1C(C)(C)C=CC2=C1C=CC(C1)=C2OC[C@H]1C1=CC=C2OC(C)(C)C=CC2=C1O CJUFYKORDZSOLF-INIZCTEOSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- LUHYCDWZJGIQKT-UHFFFAOYSA-N C(=CC(C)=C)C1=CC=C(C=C1)C=CC(=O)C1=CC=CC=C1 Chemical class C(=CC(C)=C)C1=CC=C(C=C1)C=CC(=O)C1=CC=CC=C1 LUHYCDWZJGIQKT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- LIOOJQZRNLJKMU-UHFFFAOYSA-N Demethyl coniferin Natural products OCC=Cc1ccc(OC2OC(CO)C(O)C(O)C2O)c(O)c1 LIOOJQZRNLJKMU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 208000025599 Heat Stress disease Diseases 0.000 description 1
- 206010068188 Heat illness Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- MVAUGMLUJKTORM-UHFFFAOYSA-N Licoricidin Natural products COc1cc2OCC(Cc2cc1CC=C(C)C)c3ccc(O)c(CC=C(C)C)c3O MVAUGMLUJKTORM-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GOZCEKPKECLKNO-RKQHYHRCSA-N Picein Chemical compound C1=CC(C(=O)C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GOZCEKPKECLKNO-RKQHYHRCSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- SFLMUHDGSQZDOW-FAOXUISGSA-N coniferin Chemical compound COC1=CC(\C=C\CO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-FAOXUISGSA-N 0.000 description 1
- LIOOJQZRNLJKMU-UXXRCYHCSA-N coniferin Natural products OCC=Cc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1 LIOOJQZRNLJKMU-UXXRCYHCSA-N 0.000 description 1
- SFLMUHDGSQZDOW-IBEHDNSVSA-N coniferoside Natural products COC1=CC(C=CCO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-IBEHDNSVSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IKUQEFGEUOOPGY-UHFFFAOYSA-N euoniside Natural products COC1=CC=2C=CC(=O)OC=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O IKUQEFGEUOOPGY-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- HZHXMXSXYQCAIG-UHFFFAOYSA-N hispaglabridin A Natural products CC(C)=CCC1=C(O)C=CC(C2CC3=C(C=4C=CC(C)(C)OC=4C=C3)OC2)=C1O HZHXMXSXYQCAIG-UHFFFAOYSA-N 0.000 description 1
- HZHXMXSXYQCAIG-KRWDZBQOSA-N hispaglabridin A Chemical compound CC(C)=CCC1=C(O)C=CC([C@H]2CC3=C(C=4C=CC(C)(C)OC=4C=C3)OC2)=C1O HZHXMXSXYQCAIG-KRWDZBQOSA-N 0.000 description 1
- CJUFYKORDZSOLF-MRXNPFEDSA-N hispaglabridin B Natural products Oc1c([C@H]2COc3c4c(OC(C)(C)C=C4)ccc3C2)ccc2OC(C)(C)C=Cc12 CJUFYKORDZSOLF-MRXNPFEDSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- GBRZTUJCDFSIHM-KRWDZBQOSA-N licoricidin Chemical compound C1([C@@H]2COC=3C=C(O)C(CC=C(C)C)=C(C=3C2)OC)=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-KRWDZBQOSA-N 0.000 description 1
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000009472 lonicerae flos Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910000898 sterling silver Inorganic materials 0.000 description 1
- 239000010934 sterling silver Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다. 보다 구체적으로 본 발명은 참나무 껍질, 솔잎, 감초, 갈근, 측백엽, 쑥, 금은화, 모과의 추출물을 주성분으로 하는 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다.The present invention relates to herbal extracts for preventing and eliminating hangovers and functional foods using the same. More specifically, the present invention relates to herbal extracts for hangover prevention and remedy, and functional foods using the same, including oak bark, pine needles, licorice, brown root, baekhyeop, wormwood, gold and silver, the extract of Chinese quince.
본 발명에 의할 경우, 안정성을 확보하면서 숙취를 효과적으로 예방 및 해소할 수 있게 된다. According to the present invention, it is possible to effectively prevent and eliminate hangovers while ensuring stability.
숙취, 생약 추출물, 기능성 식품, 해독, 알코올Hangover, herbal extract, functional food, detox, alcohol
Description
도 1은 본 발명의 일실시예에 의하여 제조된 추출물과 다이옥신을 투여한 경우에 있어서, 스프라그-도울리(Sprague-Dawley)의 체중변화를 나타낸 그래프이다. 1 is a graph showing the weight change of Sprague-Dawley in the case of administering the extract and dioxin prepared according to an embodiment of the present invention.
도 2는 본 발명의 일실시예에 의하여 제조된 추출물과 다이옥신을 투여한 경우에 있어서, 스프라그-도울리(Sprague-Dawley) 장기의 중량변화를 나타낸 그래프이다.Figure 2 is a graph showing the weight change of Sprague-Dawley organs in the case of administering the extract prepared by the embodiment of the present invention and dioxin.
본 발명은 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다. 보다 구체적으로 본 발명은 참나무 껍질, 솔잎, 감초, 갈근, 측백엽, 쑥, 금은화, 모과의 추출물을 주성분으로 하는 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다.The present invention relates to herbal extracts for preventing and eliminating hangovers and functional foods using the same. More specifically, the present invention relates to herbal extracts for hangover prevention and remedy, and functional foods using the same, including oak bark, pine needles, licorice, brown root, baekhyeop, wormwood, gold and silver, the extract of Chinese quince.
삭제delete
음주를 통하여 흡수된 알코올의 약 10%는 호흡이나 소변을 통해 체외로 배출되고, 나머지는 위 점막이나 간에서 대사된다. 신체에서 에틸 알코올은 아세트 알데히드로 처음 분해된 뒤, 아세트산으로 다시 분해되는데, 분해과정의 중간물질인 아세트 알데히드는 발한, 피부발열, 오심, 구토 등을 유발할 수 있으며, 정확한 원인이 밝혀지지는 않았지만 숙취의 주원인이 상기의 아세트 알데히드라고 추정되고 있다. 또한 현대인의 경우, 여러 가지 이유로 해서 음주가 잦은 편이며, 이러한 잦은 음주는 결국 신체에 무리를 주게 되어, 각종 질병의 원인이 된다. 현재 숙취제거를 위하여 많은 기술들이 개시된 바 있으나, 이들의 대부분은 과학적인 입증이 부족하거나, 원료가 희귀하여 가격면에서 상품화 되기 어렵다는 등의 여러 원인으로 인하여 상용화 되고 있지 않은 실정이다. About 10% of the alcohol absorbed through drinking is excreted in vitro through breathing or urine, and the rest is metabolized in the gastric mucosa and liver. In the body, ethyl alcohol is first decomposed to acetaldehyde and then decomposed again to acetic acid. Acetaldehyde, an intermediate in the decomposition process, can cause sweating, skin fever, nausea, vomiting, and the exact cause is not known. It is presumed that the main cause of is acetaldehyde. In addition, in the case of modern people, drinking is a frequent side for various reasons, and such frequent drinking eventually causes the body to become a cause of various diseases. Currently, many techniques have been disclosed for eliminating hangovers, but most of them have not been commercialized due to various reasons, such as lack of scientific proof or rare raw materials.
따라서 상기와 같은 문제점을 해결할 수 있는, 즉 부작용 없이 숙취해소를 할 수 있는 약제 및 식품의 개발이 절실히 요청되고 있는 실정이다. Therefore, there is an urgent need for the development of drugs and foods that can solve the above problems, that is, hangover relief without side effects.
본 발명의 목적은 안정성을 확보하면서 숙취예방 및 해소에 탁월한 효과가 있는 생약 추출물 및 이를 이용한 기능성 식품을 제공하고자 하는 것이다. An object of the present invention is to provide a herbal extract and a functional food using the same, which has an excellent effect on preventing and eliminating hangovers while ensuring stability.
삭제delete
상기의 목적 및 기타의 목적들은 하기에서 기술하는 본 발명에 의하여 모두 달성될 수 있다. The above and other objects can be achieved by the present invention described below.
본 발명은 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다. 보다 구체적으로 본 발명은 참나무 껍질, 솔잎, 감초, 갈근, 측백엽, 쑥, 금은화, 모과의 추출물을 주성분으로 하는 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품에 관한 것이다. The present invention relates to herbal extracts for preventing and eliminating hangovers and functional foods using the same. More specifically, the present invention relates to herbal extracts for hangover prevention and remedy, and functional foods using the same, including oak bark, pine needles, licorice, brown root, baekhyeop, wormwood, gold and silver, the extract of Chinese quince.
이하에서 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 참나무 껍질, 솔잎, 감초, 갈근, 측백엽, 쑥, 금은화, 모과의 추출물을 주성분으로 하는데, 우선 상기의 각 조성물이 어떠한 특성을 지니고 있으며, 어떠한 작용을 하는지에 관하여 살펴본다. The present invention is the extract of oak bark, pine needles, licorice, brown root, baekryeop, mugwort, gold and silver quince, as a main component, first of all looks at what the composition of the above, and how it works.
참나무(Quercus)는 참나무과 참나무속에 속하는 식물로서,북반구의 온대에서 열대에 걸쳐 분포하며, 우리 주위에서 쉽게 구할 수 있다. 예로부터 참나무는 목초액 등을 만드는데 활용되어져 왔으며, 목초액은 다양한 민간요법에 적용되고 있다. Oak is a plant belonging to oak and oak, distributed from temperate to tropical in the northern hemisphere and easily available around us. From ancient times, oak has been used to make vinegar liquor, which is applied to various folk remedies.
솔잎은 예로부터 한방 및 민간에서 약용이나 건강식품으로 이용되어 왔고, 동의보감에 의하면 솔잎은 위장병, 중풍, 고혈압, 신경통, 천식 등에 치료 효과가 있다고 알려져 있다. 솔잎에는 채취한 지역과 계절에 따라서 다소 차이가 있지만 일반적으로, 정유(Terpenetine Oil), 시네올(Cineol), 살리니그린(Salinigrin), 레텐(Retene), 코니페린(Coniferin), 피-사이멘(P-Cymen), 덴시피마릭산(Densipimaric Acid) 등과 엽록소, 다종의 아미노산, 조지방, 인, 철분, 효소, 미네랄, 비타민A, 비타민C, 비타민P 등이 함유되어 있다. 솔잎의 주요 성분인 정유(Terpenetine Oil)에는 알파-피넨(α-Pinene), 켐펜(Camphene), 베타-피넨(β-Pinene), 베타-미르신(β-Myrcene), 베타-펠라드렌(β-Phellandrene)등이 있는데, 이들은 모세혈관을 확장시켜 혈액순환을 촉진시킬 뿐만 아니라, 솔잎의 또 다른 함유성분인 엽록소와 함께 여러 종류의 대장균, 포도상구균, 녹농균 등에 대하여 정도는 다르지만 억제작용을 나타낸다. 또한 정유에 포함되어 있는 불포화 지방산은 혈청 콜레스테롤치를 저하시켜 상당한 혈압 강하 작용을 하며, 피부에 발생하는 습진, 음을 일으키는 병원성 진균에 대하여 항균 및 살균 작용이 있다.Pine needles have been used for medicinal and health foods in traditional medicine and private medicine. According to the agreement, pine needles are known to be effective in treating gastrointestinal diseases, stroke, hypertension, neuralgia, and asthma. Pine needles differ slightly depending on the region and season of harvest, but in general, Terpenetine Oil, Cineol, Salinigrin, Retene, Coniferin and Pi-Simen P-Cymen), Densipimaric Acid, and chlorophyll, various amino acids, crude fat, phosphorus, iron, enzymes, minerals, vitamin A, vitamin C, and vitamin P. Terpennetine oil, the main component of pine needles, contains alpha-pinene, kphene, beta-pinene, beta-myrcene, beta-felradene Shellandrene), which expands capillaries, promotes blood circulation, and, in addition to chlorophyll, another component of pine needles, has different but inhibitory effects on E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In addition, unsaturated fatty acids contained in essential oils lower serum cholesterol levels, which significantly lower blood pressure, and have antibacterial and bactericidal effects against eczema and negative pathogenic fungi occurring on the skin.
감초(Glycyrrhiza uralensis Fisch, Glycyrrhiza glabra L.)는 콩과( Leguminosae)에 속하는 다년생 초본 식물로서, 그 뿌리와 줄기는 약용 및 식용으로 사용된다. 예로부터 감초는 한방 및 민간에서 해독제, 진해거담제, 완화제, 소화성 궤양 치료제 및 위 궤양 치료제로 사용어져 왔으며, 그 외에도 근육이나 조직의 급격한 긴장에 의하여 생기는 통증을 풀어주는 작용, 항염 작용 등이 있는 것으로 알려져 왔다. 감초 추출물은 글리시리진(Glycyrrhizin), 글리시레틱산(Glycyrrhetic Acid), 리코리시딘(Licoricidin), 히스파글라브리딘 A(Hispaglabridin A), 히스파글라브리딘 B(Hispaglabridin B), 글라브리딘(Glabridin), 4-O-메틸글라브리딘(4-O-methylglabridin), 이소프레닐챨콘 유도체(Isoprenylchalcone derivative), 이소리퀴리티제닌(Isoliquiritigenin), 포르모노네틴(Formononetin) 등을 포함하고 있다. 감초 추출물 중 글리시리진(Glycyrrhizin)은 항염 작용, 해독작용, 항궤양 작용, 수전해질 호르몬 작용을 행하며, 글라브리딘(Glabridin)은 체내에서 인체에 해로운 저 밀도 인지질(Low Density Lipoprotein)의 산화를 억제시키는 효과가 있다고 알려져 있다.Licorice (Glycyrrhiza uralensis Fisch, Glycyrrhiza glabra L.) is a perennial herbaceous plant belonging to Leguminosae, whose roots and stems are used for medicinal and edible food. Licorice has long been used as an antidote, antitussive expectorant, laxative, peptic ulcer and gastric ulcer in oriental medicine and folk medicine. It has been known. Licorice extracts include Glycyrrhizin, Glycyrrhetic Acid, Licoricidin, Hispaglabridin A, Hispaglabridin B, and Glabridine (Glycyrrhizin). Glabridin, 4-O-methylglabridin, 4-isoprenylchalcone derivative, Isoliquiritigenin, Formononetin and the like. Glycyrrhizin in the licorice extract acts as an anti-inflammatory, detoxifying, anti-ulcer, and hydrolyzate hormone.Glabridin inhibits the oxidation of Low Density Lipoprotein, which is harmful to the body. It is known to be effective.
갈근은 칡(Pueraria Radix)의 주피를 제거한 뿌리로서, 한방에서는 발한(發 汗), 해열(解熱), 진경(鎭痙), 해기(解肌), 수진(遂疹), 지갈(止渴), 지사(止瀉) 등의 효능이 있는 것으로 알려져 있다. 갈근은 이소플라보노이드 (Isoflavonoide)를 다량 함유하고 있으며, 갈근과 관련한 약리 작용으로는 항알코올중독(Antidipsotropic) 작용, 간 보호 작용 ,숙취 억제 작용, 항산화 작용 등이 알려져 있다. 또한 평활근의 이완 작용, 심혈관계에서 관상동맥 확장 및 혈압 강하, 심박동 조절 작용, 혈소판 응집 억제 작용, 강혈당 작용, 해열 작용 등이 있다고 알려져 있다. The root of root is the root of the pueraria radix. It is known that there are effects such as branch offices. Brown root contains a large amount of isoflavonoide, and the pharmacological effects related to the root are known as anti-alcoholic poisoning (Antidipsotropic), liver protection, hangover suppression, and antioxidant. In addition, it is known that there is a relaxation action of smooth muscle, coronary artery dilation and blood pressure drop in the cardiovascular system, heart rate control action, platelet aggregation inhibitory action, strong blood sugar action, antipyretic action.
측백엽은 측백나무과의 측백나무(Thuja orientalis L.)의 어린 가지와 잎을 말한다. 한방에서 측백엽은 혈열을 내려 코피, 토혈, 변혈, 소변출혈, 자궁출혈에 쓰고 해수, 천식, 가래, 탈모, 지루성피부염, 외상출혈 등에 사용한다. 즉, 측백엽은 출혈시간단축, 진해, 거담작용이 있고 혈압강하, 항균작용, 해수, 천식에 효과가 있다고 알려져 있다. The cypress is the cypress ( Thuja) Orientalis L.) refers to the young branches and leaves. The herbaceous lobe from the oriental medicine to lower blood fever, nosebleeds, hemorrhage, urine bleeding, uterine hemorrhage, seawater, asthma, sputum, hair loss, seborrheic dermatitis, traumatic bleeding. In other words, the lateral lobe has been known to reduce bleeding time, cough, expectorant action, and to reduce blood pressure, antibacterial action, seawater and asthma.
쑥(mugwort)은 우리나라 뿐만 아니라 일본, 중국 등 아시아 지역과 유럽 등에 널리 분포하는 번식력이 강한 다년생 식물로서 분류학상으로 엉거시과(Carduaceae)에 속한다. 우리나라를 포함한 동양 지역에서는 코피, 자궁출혈 등에 지혈제나 소화, 하복부 진통, 구충, 악취제거, 위장병, 변비, 신경통, 냉병, 부인병 및 천식 등에 약재로서 이용되어 왔고, 그 특유의 향과 맛으로 식품의 부재료로도 널리 이용되어 왔다. 이러한 쑥은 다른 향신료와 같이 그 향기성분이나 정유성분에 살충, 항균, 항종양 등의 여러 가지 생리활성을 가지고 있는 것으로 알려져 있으며, 그 주요 성분은 시네올(cineole), α-투존(α-thujon), 세스퀴터펜(sesquiterpene), 세스퀴터펜 알코올(sesquiterpene alcohol), 캄페르(camper), 테르피넨-4-올(terpinene-4-ol), 코우마린(coumarin), 카필린(capillin), 보르네올(borneol) 등이다. Mugwort (mugwort) is a perennial plant with high propagation power, which is widely distributed in Asia, Europe, Japan, China, etc., and belongs to the Carduaceae. In oriental countries including Korea, it has been used as a medicine for hemostatics, digestion, lower abdominal pain, worms, odor removal, gastrointestinal diseases, constipation, neuralgia, cold diseases, women's diseases, and asthma, etc. It has also been widely used as a submaterial. Mugwort is known to have various physiological activities such as insecticide, antibacterial and anti-tumor in its fragrance or essential oil like other spices, and its main ingredients are cineole and α-tujon ), Sesquiterpene, sesquiterpene alcohol, sesquiterpene alcohol, camper, terpinene-4-ol, coumarin, capillin, Borneol and the like.
금은화(Lonicerae flos)는 인동과(Caprifoliaceae) 식물인 덩굴성 관목 인동덩굴(Loncera japonica)의 꽃봉오리로 한방이나 민간에서는 이뇨, 건위, 관절염, 화농성 피부염, 기관지염에 사용하고 있다. 금은화의 주요 성분은 탄닌(tannin), 이노시톨(inositol), 스테롤(sterol), 클로로제닉산(chlorogenic acid), 이소클로로제닉산(isochlorogenic acid), 아피게닌 (apigenin), 퀘르세틴(quercetin) 등이라고 알려져 있다. Lonicerae flos is a bud of the locust shrub Loncera japonica, a plant of the Caprifoliaceae family, and is used for diuresis, dry stomach, arthritis, purulent dermatitis and bronchitis in herbal and folk medicine. The main components of gold and silver are known as tannin, inositol, sterol, chlorogenic acid, isochlorogenic acid, apigenin and quercetin. have.
모과( Chaenomeles sinensis )는 중국이 원산지이며, 우리나라에는 고려 이전에 들어와 재배되고 있는 장미과에 속한 과실이다. 모과의 주요 성분은 과육인 경우 수분 74∼85 %, 당질 13.4∼20.7 %, 섬유질 1.3∼4.4 %, 회분 0.3∼0.7 %이다. 과실에는 사포닌, 사과산, 주석산, 구연산, 비타민C, 플라보노이드, 탄닌이 함유되어 있고, 종자에는 시안화수소산이 함유되어 있다. 예로부터 모과는 감기나 기관지염의 기침, 가래의 완화제로 많이 쓰이고 있다. 또한, 모과는 이질, 설사, 복통에 효능이 있고 소화 분비를 촉진시키며 위를 편안하게 하며, 보혈과 조혈작용을 해 빈혈로 인한 근육경련이나 관절통 등에 효과가 있으며, 각기병, 딸꾹질, 담, 숙취 해소작용, 더위 병에 좋다고 알려져 있다.Chinese quince (Chenomeles sinensis) is native to China and is a fruit belonging to the Rosaceae family that was cultivated before Goryeo in Korea. The main components of Chinese quince are 74-85% moisture, 13.4-20.7% sugar, 1.3-4.4% fiber and 0.3-0.7% ash. Fruits contain saponin, malic acid, tartaric acid, citric acid, vitamin C, flavonoids and tannins, and seeds contain hydrocyanic acid. Chinese quince has long been used as a cough for phlegm and bronchitis. In addition, quince is effective in dysentery, diarrhea and abdominal pain, promotes digestion and relaxes the stomach, and it is effective for muscle spasms and joint pain caused by anemia by relieving the spores, hiccups, phlegm and hangover. It is said that it is good for action, heat illness.
본 발명, 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품을 구성하는 각각의 조성물은 각각의 건조중량을 기준으로 하여, 참나무 껍질 25 내지 75 중량부, 솔잎 30 내지 90 중량부, 감초 6 내지 18 중량부, 갈근 30 내지 90 중량부, 측백엽 6 내지 18 중량부, 쑥 6 내지 18 중량부, 금은화 1 내지 3 중량부, 모과 2 내지 6 중량부의 비로 조합하며, 바람직하게는 참나무 껍질 50 중량부, 솔잎 60 중량부, 감초 12 중량부, 갈근 60 중량부, 측백엽 12 중량부, 쑥 12 중량부, 금은화 2 중량부, 모과 4 중량부의 비로 조합한다. 상기와 같이 본 발명에서 사용하는 생약제의 조성물은 오래전부터의 사용으로 인해 안전성이 확보된 것으로서, 독성 및 부작용이 없다는 장점이 있는데, 이는 화학물질 사용시 수반되는 여러 가지 독성과 생리조절 기능의 부조화 등 부작용을 고려할 때 커다란 잇점이 될 수 있는 것이다.The present invention, each composition constituting the herbal extracts for preventing and eliminating hangovers and functional foods using the same, based on the dry weight of each, 25 to 75 parts by weight of oak bark, 30 to 90 parts by weight of pine needles, licorice 6 to 18 parts by weight, brown root 30 to 90 parts by weight, 6 to 18 parts by weight of the locust leaf, 6 to 18 parts by weight of wormwood, 1 to 3 parts by weight of sterling silver, 2 to 6 parts by weight of quince, preferably 50 parts by weight of oak bark , 60 parts by weight of pine needles, 12 parts by weight of licorice, 60 parts by weight of root roots, 12 parts by weight of baekryeop, 12 parts by weight of wormwood, 2 parts by weight of gold and silver, and 4 parts by weight of Chinese quince. As described above, the composition of the herbal medicines used in the present invention has a safety as a result of long-term use, and has the advantage of no toxicity and side effects, which are various side effects such as incompatibility of various toxic and physiological control functions when using chemicals. This can be a big advantage when considering.
또한 본 발명에 따른 숙취예방 및 해소를 위한 생약 추출물은 추출의 대상이 되는 상기 참나무 껍질, 솔잎, 감초, 갈근, 측백엽, 쑥, 금은화, 모과의 전체 중량의 50 내지 150배의 정제수를 가한 후, 20 내지 40℃의 상온에서 24시간 이상 추출을 한 다음, 40 내지 80℃의 고온에서 24시간 이상 추출을 행하고, 최종적으로 100℃로 가열하여 기화하는 증기를 포집하여 냉각시킴으로써 제조된다. 상기와 같이 20 내지 40℃의 상온에서 24시간 이상, 40 내지 80℃의 고온에서 24시간 이상의 추출을 순차적으로 행하는 것은 추출의 효과를 높이기 위한 것이며, 이는 본 발명의 발명자들이 다수의 반복실험을 하여 찾아낸 것이다. In addition, the herbal extract for preventing and eliminating hangover according to the present invention, after adding 50 to 150 times the total weight of the oak bark, pine needles, licorice, brown root, baekyeop, mugwort, gold and silver quince, which is subject to extraction, The extraction is performed at room temperature of 20 to 40 ° C. for at least 24 hours, followed by extraction at a high temperature of 40 to 80 ° C. for at least 24 hours, and finally, the vapor is heated to 100 ° C. to be collected and cooled. As described above, the extraction is sequentially performed at a temperature of 20 to 40 ° C. for 24 hours or more and at a high temperature of 40 to 80 ° C. for 24 hours to increase the effect of extraction, and the inventors of the present invention perform a plurality of repeated experiments. I found it.
본 발명, 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품의 경우 액상, 과립상, 분체상, 겔상 등 어떠한 형태로도 제조될 수 있으며, 유제, 정제, 캅셀제, 과립제, 산제, 시럽제 등으로 제조될 수도 있다. 또한 본 발명에 의한 생약 추출물 및 이를 이용한 기능성 식품은 숙취예방 및 해소뿐 아니라 다이옥신 등의 독성물질의 해독과 알코올 섭취에 따른 간기능 저하를 방지할 수 있으며, 이의 구체적인 내용은 하기의 실시예 및 시험예에서 후술한다. In the present invention, herbal extracts for preventing and eliminating hangovers and functional foods using the same can be prepared in any form, such as liquid, granular, powdery, gelled, emulsions, tablets, capsules, granules, powders, syrups, etc. It may also be prepared. In addition, herbal extracts and functional foods using the same according to the present invention can prevent and relieve hangover as well as prevent detoxification of toxic substances such as dioxins and deterioration of liver function due to alcohol intake. An example will be described later.
유제와 시럽제와 같은 액체 조성물은 물, 당류, 유류, 비타민, 색소, 무기질, 방부제 등을 첨가제로 사용하여 제조할 수 있으며, 캅셀제, 정제, 산제, 과립제 등은 부형제, 붕괴제, 활택제, 결합제, 계면활성제, 가소제 등을 첨가제로 사용해서 제조할 수 있다. Liquid compositions such as emulsions and syrups can be prepared using water, sugars, oils, vitamins, pigments, minerals, and preservatives as additives.Capsules, tablets, powders, granules, etc. are excipients, disintegrants, lubricants, binders. , Surfactants, plasticizers and the like can be used as additives.
이하에서는 실시예 및 시험예에 의하여 본 발명을 더욱 구체적으로 설명하도록 한다. 단 본 발명이 하기의 실시예 및 시험예에 의하여 제한되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, the present invention is not limited by the following Examples and Test Examples.
실시예Example 1 : 생약 추출물의 제조 1: Preparation of herbal extract
밀폐된 용기에 참나무 250g, 솔잎 300g, 감초 60g, 갈근 300g, 측백 60g, 쑥 60g, 금은화 10g, 모과 20g을 혼합하여 넣고, 상기 혼합물에 100ℓ의 정제수를 가한 후, 30℃에서 24시간, 60℃에서 24시간 추출을 하였다. 그 후에 100℃로 가열하고 기화되는 증기를 포집하여 냉각함으로써 추출을 완료하였다. 250 g of oak, 300 g of pine needles, licorice 60 g, brown root 300 g, white liquor, wormwood 60 g, gold and silver ginseng 10 g, Chinese quince 20 g are mixed in a sealed container, and 100 l of purified water is added to the mixture. Extraction was performed for 24 hours at. The extraction was then completed by heating to 100 ° C. and collecting and cooling the vaporized vapor.
실시예2Example 2 : 생약 추출물의 제조 : Preparation of Herbal Extracts
상기의 실시예 1에 의한 생약 추출물에 있을지 모르는 불순물을 제거하기 위하여 에탄올로 2회 추출하는 과정을 수행하였다. 즉, 상기 실시예 1에 의한 생약 추출물 1ℓ를 취하고 여기에 100% 에탄올 1ℓ를 가하여 50% 에탄올 용액으로 만든 뒤, 상온에서 24시간 방치한 후에 여과하고 에탄올을 증발시키는 과정을 거친 후 얻어진 1ℓ의 액에 100% 에탄올 1ℓ를 다시 가하여 50% 에탄올 용액으로 만든 뒤, 0-4℃의 온도에서 24시간 방치한 후에 여과하고, 에탄올을 증발시켜 1ℓ의 액을 얻 었다.In order to remove impurities that may be present in the herbal extract according to Example 1, the extraction was performed twice with ethanol. That is, 1 liter of the herbal extract according to Example 1 was taken, and 1 liter of 100% ethanol was added thereto to make a 50% ethanol solution, which was left at room temperature for 24 hours, followed by filtration and evaporation of ethanol. To 1 liter of 100% ethanol was added again to make a 50% ethanol solution, and left for 24 hours at a temperature of 0-4 ℃, filtered and ethanol was evaporated to obtain a 1 liter of liquid.
시험예1Test Example 1 : 안정성 시험 : Stability Test
실험동물은 체중 180-200g(평균체중 190g)스프라그-도울리(Sprague-Dawley)계 웅성 랫트를 1주일 순화시킨 뒤 사용했고, 각 군당 10마리를 설정하여 실험을 수행하였다. 실험동물 사육실 온도는 23±2℃, 습도 50±20%를 유지했으며, light/dark 주기를 12시간으로 하였다. 상기의 실험동물에 상기의 실시예 1에 의하여 제조된 추출물 및 상기의 실시예 2에 의하여 제조된 추출물 20mg/kg·day를 경구투여하고 생존여부(72hr)를 관찰한 결과, 주어진 기간 내에 모두 생존하였고, 10g/kg·day의 투여량에서도 LD50을 관찰할 수 없었다. Experimental animals were used after 1 week of body weight 180-200g (average weight 190g) Sprague-Dawley male rats were purified, and 10 animals were set in each group. The experimental animal breeding room temperature was maintained at 23 ± 2 ℃, humidity 50 ± 20%, and the light / dark cycle was 12 hours. As a result of oral administration of the extract prepared according to Example 1 and 20 mg / kg · day of the extract prepared according to Example 2 to the experimental animal and observing survival (72hr), all survive within a given period. LD 50 could not be observed even at the dose of 10 g / kg · day.
또한, 상기의 용량을 30일간 지속적으로 경구투여 하였을 경우에도 모두 생존하였으며, 상기의 추출물을 투여하지 않은 대조군과 비교 하였을 때, 체중과 활동성 면에서 유의할만한 변화를 감지할 수 없었다. In addition, all of these doses survived even if administered orally continuously for 30 days, and compared with the control group not administered the extract, significant changes in weight and activity could not be detected.
시험예Test Example 2 : 해독 시험 2: detoxification test
실험동물은 체중 180-200g(평균체중 190g)스프라그-도울리(Sprague-Dawley)계 웅성 랫트를 1주일 순화시킨 뒤 사용했고, 각 군당 10마리를 설정하여 실험을 수행하였다. 실험동물 사육실 온도는 23±2℃, 습도 50±20%를 유지했으며, light/dark 주기를 12시간으로 하였다. 상기의 실험동물을 대상으로 하여 본 발명 에 의한 생약 추출물의 다이옥신 해독효과를 시험하였다. 다이옥신으로는 TCDD가 이용되었다. 일군(제1처치군)에는 다이옥신 1㎍/KG·day를 30일간 복강투여 하였고, 다른 일군(제2처치군)에는 다이옥신 1㎍/kg·day와 상기 실시예 2에 의한 생약 추출물 20mg/kg·day을 30일간 복강투여 하였다. 다이옥신과 생약 추출물을 투여하지 않은 실험동물이 대조군으로 활용되었다. Experimental animals were used after 1 week of body weight 180-200g (average weight 190g) Sprague-Dawley male rats were purified, and 10 animals were set in each group. The experimental animal breeding room temperature was maintained at 23 ± 2 ℃, humidity 50 ± 20%, and the light / dark cycle was 12 hours. The dioxin detoxification effect of the herbal extract according to the present invention was tested in the above experimental animals. TCDD was used as dioxin. One group (first treatment group) was intraperitoneally administered 1 ug / KG · day of dioxin for 30 days, and the other group (second treatment group) 1 ug / kg · day of dioxin and 20 mg / kg of herbal extracts according to Example 2 Day was intraperitoneally administered for 30 days. Experimental animals that did not receive dioxins and herbal extracts were used as controls.
(1) 체중 측정(1) weight measurement
대조군, 제1처치군, 제2처치군에 대하여 각각 5일, 10일, 15일, 20일, 25일, 30일 투여후의 체중을 측정하여 아래의 표 1 및 도 1에 나타내었다.The body weights of the control group, the first treatment group, and the second treatment group were measured after 5 days, 10 days, 15 days, 20 days, 25 days, and 30 days, respectively, and are shown in Table 1 and FIG. 1 below.
[표 1] 체중 측정 결과 [Table 1] Weight measurement results
상기의 표 1에서 보여 지듯이 제1처치군의 경우, 대조군에 비하여 성장이 둔화됨을 알 수 있고, 특히, 다이옥신을 20일간 주입하였을 때에는 체중이 오히려 감소함을 알 수 있었다. 제2처치군의 경우에는 비록 대조군에 비하여 성장이 다소 둔화되기는 하나, 제1처치군과 비교하였을 때에는 그 둔화세가 상당히 완화됨을 알 수 있었다. 따라서, 본 발명에 의한 생약 추출물의 경우 다이옥신에 의한 성장둔화 및 체중감소를 방지하는 데에 효과가 있음을 알 수 있다. As shown in Table 1 above, in the first treatment group, the growth was slowed compared to the control group, and in particular, when the dioxin was injected for 20 days, the weight was decreased. In the second treatment group, although the growth was slightly slower than the control group, the slowdown was considerably alleviated when compared to the first treatment group. Therefore, it can be seen that the herbal extract according to the present invention is effective in preventing growth slowdown and weight loss by dioxin.
(2) 장기의 중량 측정(2) weighing organs
실험개시 30일 후에 대조군, 제1처치군, 제2처치군에 대하여 간, 신장, 고환의 중량을 측정하여 아래의 표 2 및 도 2에 나타내었다.30 days after the start of the experiment, the weights of the liver, kidney, and testicles were measured for the control group, the first treatment group, and the second treatment group, and are shown in Table 2 and FIG. 2 below.
[표 2] 장기 중량 측정 결과 [Table 2] long-term weight measurement results
상기의 표 2에서 보여 지듯이 다이옥신만을 처치한 제1처치군의 경우는 간, 신장, 고환 모두 중량이 현저히 감소함을 알 수 있었다. 대조군과 비교하여 간의 경우는 약 62%, 신장의 경우는 약 70%, 고환의 경우는 약 50%의 중량에 불과함을 알 수 있었다. 다이옥신과 생약 추출물을 동시에 투여한 제2처치군의 경우, 대조군에 비하여 중량감소가 있었으나, 그 감소정도가 다이옥신만을 처치한 제1처치군에 비하여 현저히 줄었음을 알 수 있었다. 제2처치군의 경우 대조군과 비교하여, 간의 경우는 약 91%, 신장의 경우는 약 88%, 고환의 경우는 약 94%의 중량을 유지함을 알 수 있었다. 따라서, 본 발명에 의한 생약 추출물의 경우 다이옥신에 의 한 장기의 중량 감소 및 기능저하를 방지하는 데에 효과가 있음을 알 수 있다. As shown in Table 2, in the first treatment group treated with only dioxin, the weights of the liver, kidney, and testes were significantly reduced. Compared with the control group, the liver was about 62%, the kidney was about 70%, and the testicles were only about 50% by weight. In the second treatment group administered dioxins and herbal extracts at the same time, there was a decrease in weight compared to the control group, but the reduction was significantly reduced compared to the first treatment group treated with dioxin alone. Compared to the control group in the second treatment group, it was found that the weight of the liver was about 91%, the kidney was about 88%, and the testicles were about 94%. Therefore, it can be seen that the herbal extract according to the present invention is effective in preventing weight loss and deterioration of organs by dioxin.
시험예Test Example 2 : 알코올 섭취에 따른 간 손상 방지 및 알코올 분해 효능 시험 2: prevention of liver damage and alcohol degradation efficacy test by alcohol consumption
(1) 알코올 분해 효과(1) alcohol decomposition effect
실험동물은 체중 180-200g(평균체중 190g) 스프라그-도울리(Sprague-Dawley)계 웅성 랫트를 1주일 순화시킨 뒤 사용했고, 각 군당 10마리를 설정하여 실험을 수행하였다. 실험동물 사육실 온도는 23±2℃, 습도 50±20%를 유지했으며, light/dark 주기를 12시간으로 하였다. 상기의 실험동물을 대상으로 하여 알코올 분해에 대한 본 발명의 효과를 시험하였다. 일군(제1처치군)에는 생수 20mg/kg을 경구투여 한 후, 1시간 후에 25% 에틸 알코올 2mg/kg을 경구투여 하였고, 다른 일군(제2처치군)에는 상기 실시예 1에 의한 생약 추출물 20mg/kg을 경구 투여 한 후, 1시간 후에 25% 에틸알코올 2mg/kg을 경구투여 하였다. 에틸 알코올 투여 후 2시간 후에 안와 정맥으로부터 혈액을 채취하여, 3,000rpm에서 10분간 원심분리한 후,상등액을 분리하고 혈중 알코올 농도를 에탄올 정량 키트(Sigma 332-A, USA)를 사용하여 측정하였다. 측정결과 제1처치군의 알코올 농도(mg/ml)는 0.07±0.007, 제2처치군의 알코올 농도는 0.02±0.002 이었다. 상기의 측정 결과에서 보여 지듯이 알코올만을 투여한 제1처치군에 비하여, 알코올과 본 발명에 의한 추출물을 동시에 투여한 제2처치군의 경우가 혈중 알코올 농도가 현저히 낮음을 알 수 있다. 따라서 본 발명에 의한 추출물의 경우 알코올에 분해를 촉진하는 데에 탁월한 효과가 있음을 알 수 있다. Experimental animals were used after a week-long purifying Sprague-Dawley male rat body weight 180-200g (average weight 190g) Sprague-Dawley male rats, the experiment was set to 10 dogs in each group. The experimental animal breeding room temperature was maintained at 23 ± 2 ℃, humidity 50 ± 20%, and the light / dark cycle was 12 hours. The experimental animals were tested for the effects of the present invention on alcohol degradation. One group (first treatment group) was orally administered with 20mg / kg of bottled water, and after 1 hour, 25% ethyl alcohol 2mg / kg was orally administered, and the other group (second treatment group) had the herbal extract according to Example 1 above. After oral administration of 20 mg / kg, 2 mg / kg of 25% ethyl alcohol was orally administered 1 hour later. 2 hours after the administration of ethyl alcohol, blood was collected from the orbital vein, centrifuged at 3,000 rpm for 10 minutes, the supernatant was separated, and the blood alcohol concentration was measured using an ethanol quantitative kit (Sigma 332-A, USA). As a result, the alcohol concentration (mg / ml) of the first treatment group was 0.07 ± 0.007, and the alcohol concentration of the second treatment group was 0.02 ± 0.002. As shown in the above measurement results, it can be seen that the blood alcohol concentration is significantly lower in the second treatment group in which the alcohol and the extract according to the present invention are administered in comparison with the first treatment group in which only the alcohol is administered. Therefore, it can be seen that the extract according to the present invention has an excellent effect on promoting degradation in alcohol.
(2) 간 보호 효과(2) liver protection effect
실험동물은 체중 180-200g(평균체중 190g)스프라그-도울리(Sprague-Dawley)계 웅성 랫트를 1주일 순화시킨 뒤 사용했고, 각 군당 10마리를 설정하여 실험을 수행하였다. 실험동물 사육실 온도는 23±2℃, 습도 50±20%를 유지했으며, light/dark 주기를 12시간으로 하였다. 상기의 실험동물을 대상으로 하여 알코올 섭취에 의해 유발되는 간 손상에 대한 본 발명의 보호 효과를 시험하였다. 일군(제1처치군)에는 25% 에틸알코올 2mg/kg·day을 30일간 경구투여 하였고, 다른 일군(제2처치군)에는 25% 에틸알코올 2mg/kg·day과 상기 실시예 1에 의한 생약 추출물 20mg/kg·day을 30일간 경구투여 하였다. 알코올과 생약 추출물을 투여하지 않은 실험동물이 대조군으로 활용되었다.Experimental animals were used after 1 week of body weight 180-200g (average weight 190g) Sprague-Dawley male rats were purified, and 10 animals were set in each group. The experimental animal breeding room temperature was maintained at 23 ± 2 ℃, humidity 50 ± 20%, and the light / dark cycle was 12 hours. The experimental animals were tested for the protective effect of the present invention against liver damage caused by alcohol intake. One group (first treatment group) was orally administered with 25% ethyl alcohol 2mg / kg · day for 30 days, and the other group (second treatment group) 25% ethyl alcohol 2 mg / kg · day and the herbal medicine according to Example 1 Extract 20mg / kg · day was orally administered for 30 days. Experimental animals that did not receive alcohol and herbal extracts were used as controls.
실험개시 30일 후 실험동물의 간을 절제하여 SF/IC(CH-16, Texas Intern社)를 사용하여 GOP 및 GTP를 측정하였고, 그 결과를 아래의 표 4에 나타내었다. After 30 days from the start of the experiment, the livers of the animals were excised to measure GOP and GTP using SF / IC (CH-16, Texas Intern), and the results are shown in Table 4 below.
[표 3] GOP/GTP 측정 결과 [Table 3] GOP / GTP Measurement Results
상기의 표 3에서 보여지듯이 알코올만을 투여한 제1처치군에 비하여, 알코올과 본 발명에 의한 조성물을 동시에 투여한 제2처치군의 경우가 GOP와 GPT 모두 수 치가 현저히 낮음을 알 수 있다. 따라서 본 발명에 의한 추출물의 경우 알코올에 의한 간 손상을 방지하는 데에 탁월한 효과가 있음을 알 수 있다. As shown in Table 3 above, it can be seen that the values of both GOP and GPT are significantly lower in the second treatment group in which the alcohol and the composition according to the present invention are simultaneously administered compared to the first treatment group in which only the alcohol is administered. Therefore, it can be seen that the extract according to the present invention has an excellent effect in preventing liver damage by alcohol.
실시예Example 3 : 알코올 분해 및 숙취제거 기능을 갖는 음료의 제조 3: preparation of beverage having alcohol decomposition and hangover removal function
상기 실시예 1 및 실시예 2의 생약 추출물에 각종 첨가물을 더하여 기능성 음료를 제조 하였다. 각각의 구체적인 조성은 하기의 표 4와 같다. Functional beverages were prepared by adding various additives to the herbal extracts of Examples 1 and 2. Each specific composition is shown in Table 4 below.
[표 4] 기능성 음료의 조성비 [Table 4] Composition ratio of functional drinks
시험예Test Example 3 : 알코올 분해 및 숙취 제거 효능의 시험 3: Test of Alcohol Degradation and Hangover Efficacy
(1) 알코올 분해 효능 시험(1) alcohol degradation efficacy test
20세 내지 40세의 신체건강한 남녀 각 5명(남자 체중 평균 : 72kg, 여자 체중 평균 : 56kg)에게 알코올 함량 21%의 소주 360ml를 1시간 동안 음용케 한 후, 알코올 농도 측정기(CA-2000)를 이용하여 1시간 간격으로 혈중 알코올 농도를 측정하여, 이를 비교예로 하였다. After 5 hours of drinking 20ml of alcoholic beverages for 21 hours, the alcohol concentration meter (CA-2000) Blood alcohol concentration was measured at 1 hour intervals by using the above as a comparative example.
이틀 경과 후, 상기의 남녀에게 상기 실시예 3의 제조예 1의 음료 100ml를 먼저 음용케 한 후에, 알코올 함량 21%의 소주 360ml를 1시간 동안 음용케 한 후, 알코올 농도 측정기를 이용하여 1시간 간격으로 혈중 알코올 농도를 측정하였다(측정예 1). After two days, the male and female to drink 100ml of the beverage of Preparation Example 1 of Example 3 first, and then to drink alcoholic beverages 360ml of 21% alcohol content for 1 hour, 1 hour using an alcohol concentration meter Blood alcohol concentration was measured at intervals (Measurement Example 1).
다시 이틀이 지난 후에, 상기의 남녀에게 알코올 함량 21%의 소주 360ml를 1시간 동안 음용케 한 후, 상기 실시예 3의 제조예 1의 음료 100ml를 음용케 하여, 알코올 농도 측정기를 이용하여 1시간 간격으로 혈중 알코올 농도를 측정하였다(측정예 1′).After two more days, the men and women were allowed to drink 360 ml of alcoholic beverages containing 21% alcohol for 1 hour, and then drink 100 ml of the beverage of Preparation Example 1 of Example 3, and then drink the alcohol concentration meter for 1 hour. Blood alcohol concentrations were measured at intervals (Measurement Example 1 ').
상기 실시예 3의 제조예 2 내지 제조예 4에 대해서도 제조예 1과 같은 방식으로 테스트를 하여 혈중 알코올 농도를 측정하였다(측정예 2 내지 4′). 측정결과의 평균값을 하기의 표 5에 나타내었다. In the same manner as in Preparation Example 1 was also tested for Preparation Examples 2 to 4 of Example 3 to determine the blood alcohol concentration (Measuring Examples 2 to 4 '). The average value of the measurement results is shown in Table 5 below.
[표 5] 혈중 알코올 농도 측정 결과 [Table 5] Blood alcohol concentration measurement results
상기의 표 5에서 보여 지듯이 알코올만 섭취한 비교예에 비하여 알코올과 기능성 음료를 같이 섭취한 경우의 혈중 알코올 농도가 낮아지게 됨을 알 수 있었다. 상기의 표에서 알 수 있듯이 기능성 음료에 상기 실시예의 조성물의 함량이 50wt%인 경우가 조성물의 함량이 25wt% 인 경우보다 혈중 알코올 농도를 보다 낮게 함을 알 수 있었다. 그러나 상기의 표에서 확인 할 수 있듯이 조성물의 함량이 동일하다면, 실시예 1의 추출물을 첨가한 음료인지 실시예 2의 추출물을 첨가한 음료인지는 알코올 농도에 별다른 영향을 미치지 못함을 알 수 있다. 또한 3시간 후의 혈중 알코올 농도를 측정 하였을 때, 상기의 음료를 알코올 섭취 전에 음용하는 것이 혈중 알코올 농도를 보다 낮게 하는 것으로 나타나고 있으며, 이는 음료의 기능이 체내에서 발현되는 시간이 상대적으로 긴 것에 기인하는 것으로 판단된다. As shown in Table 5 above, it was found that the blood alcohol concentration was lowered when the alcohol and the functional beverage were ingested in comparison with the comparative example in which only the alcohol was ingested. As can be seen from the above table, the content of the composition of the above embodiment in the functional beverage was found to lower the blood alcohol concentration than the case of the composition of 25wt%. However, as can be seen in the above table, if the content of the composition is the same, it can be seen that whether the beverage is added to the extract of Example 1 or the beverage is added to the extract of Example 2 does not affect the alcohol concentration. In addition, when the blood alcohol concentration was measured after 3 hours, it was shown that drinking the above beverage before ingesting the alcohol lowers the blood alcohol concentration, which is due to the relatively long time for the function of the beverage to be expressed in the body. It seems to be.
(2) 숙취제거 효능 시험(2) Hangover Efficacy Test
상기의 “(1) 알코올 분해 효능 시험”완료 후 9시간 후에, 즉 알코올 섭취 후, 12시간 후에 참여인원에게 숙취와 두통의 정도를 평가하게 하여, 그 결과를 하기의 표 6에 나타내었다. 숙취 및 두통의 평가는 상기의 “(1) 알코올 분해 효능 시험”의 “측정예 1, 2, 3, 4”에 대하여 시행하였다. 숙취 및 두통의 정도는 전혀없음(5), 없음(4), 보통(3), 약간 있음(2), 매우 심함(1)으로 구분하였고, 결과는 평균값으로 나타내었다. Nine hours after the completion of the "(1) alcohol degradation efficacy test", that is, 12 hours after alcohol intake, the participants were evaluated for the degree of hangover and headache, and the results are shown in Table 6 below. The evaluation of hangover and headache was performed with respect to "Measurement example 1, 2, 3, 4" of the "(1) alcohol degradation efficacy test". The degree of hangover and headache were divided into none (5), none (4), moderate (3), mild (2), and severe (1). The results were expressed as mean values.
[표 6] 숙취 및 두통 평가 결과 [Table 6] Hangover and headache evaluation results
상기의 표 6에서 보여지듯이 알코올만 섭취한 비교예에 비하여 알코올과 기능성 음료를 같이 섭취한 경우에 숙취 및 두통의 정도가 현저히 완화됨을 확인할 수 있었다. As shown in Table 6 above, it was confirmed that the degree of hangover and headache was remarkably alleviated when the alcohol and the functional beverage were ingested in comparison with the alcohol-only comparative example.
상기한 바와 같이, 본 발명, 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품의 경우, 안정성을 확보하면서 숙취를 효과적으로 예방 및 제거할 수 있게 된다. As described above, in the case of the present invention, herbal extracts for preventing and eliminating hangovers and functional foods using the same, it is possible to effectively prevent and remove hangovers while ensuring stability.
삭제delete
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060099815A KR100915893B1 (en) | 2006-10-13 | 2006-10-13 | Herb Extracts and Functional Food using the same for Obviating and Curing Hangover |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060099815A KR100915893B1 (en) | 2006-10-13 | 2006-10-13 | Herb Extracts and Functional Food using the same for Obviating and Curing Hangover |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080107259A Division KR20080101848A (en) | 2008-10-30 | 2008-10-30 | Herb extracts and functional food using the same for obviating and curing hangover |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080033737A KR20080033737A (en) | 2008-04-17 |
KR100915893B1 true KR100915893B1 (en) | 2009-09-07 |
Family
ID=39573584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060099815A KR100915893B1 (en) | 2006-10-13 | 2006-10-13 | Herb Extracts and Functional Food using the same for Obviating and Curing Hangover |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100915893B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103355671A (en) * | 2013-06-28 | 2013-10-23 | 成进学 | Nano-element longevity capsule capable of increasing propagation rate of cell genes |
KR102282839B1 (en) * | 2019-04-30 | 2021-07-28 | 주식회사 엘지생활건강 | Composition for relieving or improving hangover |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920005999A (en) * | 1990-09-13 | 1992-04-27 | 김영기 | Manufacturing method of antidote based on pure herbal medicine |
KR970009807A (en) * | 1995-08-17 | 1997-03-27 | 백재기 | Antidote composition using plant herbals |
KR20010036048A (en) * | 1999-10-05 | 2001-05-07 | 천경호 | Beverage composition for protection drunkage |
KR20030010259A (en) * | 2001-07-26 | 2003-02-05 | 남정춘 | Antidotes of crude drugs and fabrication method thereof |
-
2006
- 2006-10-13 KR KR1020060099815A patent/KR100915893B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920005999A (en) * | 1990-09-13 | 1992-04-27 | 김영기 | Manufacturing method of antidote based on pure herbal medicine |
KR970009807A (en) * | 1995-08-17 | 1997-03-27 | 백재기 | Antidote composition using plant herbals |
KR20010036048A (en) * | 1999-10-05 | 2001-05-07 | 천경호 | Beverage composition for protection drunkage |
KR20030010259A (en) * | 2001-07-26 | 2003-02-05 | 남정춘 | Antidotes of crude drugs and fabrication method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20080033737A (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DeFilipps et al. | The medicinal plants of Myanmar | |
Shikov et al. | Medicinal plants of the Russian Pharmacopoeia; their history and applications | |
Khare | Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany | |
Khare | Indian medicinal plants: an illustrated dictionary | |
Khan et al. | Olea europaea: a phyto-pharmacological review | |
Qasem | Prospects of wild medicinal and industrial plants of saline habitats in the Jordan valley | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
Eze et al. | Phytochemical and nutrient evaluation of the leaves and fruits of Nauclea latifolia (Uvuru-ilu) | |
KR100976816B1 (en) | Composition for solving hangover and improving bowel and kidney function, and process for preparing the same | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
JP2003192605A (en) | Lipase inhibitant | |
Akintola et al. | Nutritional and medicinal importance of Tetrapleura tetraptera fruits (Aridan) | |
Osuntokun | Efficacy, properties and therapeutic use of some major medicinal plants for human health | |
Okwu | Nigerian medicinal plants I | |
WO2018035706A1 (en) | Traditional chinese medicine preparation for atopic dermatitis, preparation method therefor and use thereof | |
WO2002066041A1 (en) | Natural composition | |
KR100915893B1 (en) | Herb Extracts and Functional Food using the same for Obviating and Curing Hangover | |
KR20080101848A (en) | Herb extracts and functional food using the same for obviating and curing hangover | |
KR20100041284A (en) | The method and the beverage which are good for getting out of drunken condition and for liver function | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
Rimple et al. | Poly pharmacological effects of green blood therapy: An update | |
Chillemi | The complete guide to natural healing: a natural approach to healing the body and maintaining optimal health using herbal supplements, vitamins, minerals, fruits, vegetables and alternative medicine | |
KR102136053B1 (en) | Composition for Removing Hangover Comprising Herb Extract and Beverage Thereof | |
RU2435450C1 (en) | Biologically active dietary supplement origitea® ochischeniye vecher | |
Kamaei et al. | Comparison of Antidiabetic Effects of Aqueous Extract of the Leaves and Fruits of Avicennia Marina in Streptozotocin-induced Diabetic Male Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121010 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131018 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140820 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151013 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |